Therapy and Antidepressants Aren't Helping My Grief — What Else Can I Try?

Why Grief Can Stay Stuck Even When You're Doing Everything Right

You have tried therapy. You may have tried antidepressants. You are still stuck.

Exhaustion and self-blame are common when you feel like you are doing everything right but nothing is changing. That lack of progress is not a character flaw. It may be a mismatch between your condition and the treatments you have been offered.

Prolonged grief disorder is now formally recognized as a distinct medical condition in both the DSM-5-TR and the ICD-11. It affects approximately 7 to 10% of bereaved adults.¹

The condition is characterized by symptoms that last beyond 12 months in the DSM-5-TR or 6 months in the ICD-11.² While it frequently co-occurs with depression, prolonged grief disorder is a separate condition with its own neurobiology.

Hallmark symptoms include:

• Persistent yearning: Experiencing intense longing for the deceased person.
• Identity disruption: Feeling like a part of yourself has died.
• Emotional numbness: Having difficulty experiencing positive feelings.
• Social withdrawal: Struggling to re-engage with daily life and relationships.
• Functional impairment: Finding it difficult to work or socialize normally.

Most people experiencing prolonged grief disorder receive interventions designed for depression or general bereavement, and that mismatch is the core problem. Antidepressants target serotonin and depression neurobiology. Standard grief counseling addresses emotional processing but may not target the specific mechanisms of prolonged grief.

The researchers who ran the largest grief pharmacotherapy trial to date put it plainly: "complicated grief is a specific condition in need of a specific treatment."³ Prolonged grief is not primarily a sadness disorder. It is an identity disorder.

When someone central to your life dies, you lose the version of yourself that existed with them. Standard depression protocols do not address the profound identity disruption that follows.

Why Antidepressants Often Don't Successfully Treat Grief

In controlled trials, antidepressants have not been shown to reduce grief symptoms better than a placebo. They may help alleviate co-occurring depression, but the grief itself is a completely different target.

In the largest grief pharmacotherapy trial to date involving 395 participants, the SSRI citalopram was no better than a placebo for grief at either 12 or 20 weeks.³ Adding citalopram to grief therapy added nothing to the overall grief outcomes.

The medication did improve co-occurring depression, but it did not resolve the grief itself. Key findings from the trial include:

• No standalone benefit: Citalopram alone did not outperform placebo for grief symptom reduction.
• No combination benefit: Combining citalopram with grief therapy did not improve grief outcomes beyond therapy alone.
• Depression relief: Citalopram was effective at reducing depressive symptoms in the same patients.

A separate four-arm randomized controlled trial of the tricyclic antidepressant nortriptyline for bereavement-related depression showed similar results in 80 participants.⁴ Nortriptyline significantly improved depression but showed no differential effect on grief.

Grief symptoms fell by the same amount in every arm of the study, whether participants received the drug or the placebo. The authors noted that grief does not resolve with the same clarity as depression. The trial demonstrated a controlled dissociation where the drug moved the depression but not the grief.

If you have been prescribed an antidepressant after a loss and it helped your mood but not your grief, the data explains why. Grief and depression are overlapping but separate targets, and treating one does not automatically treat the other. If grief is the primary problem, it requires an approach that targets grief directly.

What Grief Therapy Actually Works and What It Requires

Complicated Grief Treatment is the most evidence-backed psychotherapy for prolonged grief disorder. It is also called Prolonged Grief Disorder Therapy.

The protocol was developed for complicated grief from the ground up rather than being adapted from standard depression or trauma therapy. It has been tested in a number of randomized controlled trials, demonstrating response rates between 66 and 83%.^3,5,11

Complicated Grief Treatment is a highly defined treatment framework delivered by a specially trained therapist, typically running 16 sessions over approximately 20 weeks. The therapy combines cognitive behavioral techniques with highly specific grief work. Core components of the protocol include:

• Revisiting the loss: Telling the story of the death to process the reality of it.
• Addressing avoidance: Confronting situations or places that keep the grief stuck.
• Rebuilding identity: Creating a sense of self and future orientation without the deceased.
• Restoring function: Engaging in specific exercises to improve daily living.

The primary challenge with Complicated Grief Treatment is access. It requires a therapist specifically trained in the protocol.

These specialists are generally available only at academic medical centers or specialty grief clinics. Most people experiencing prolonged grief disorder simply do not have access to a trained therapist.

For people who cannot access the therapy, or who have tried it and not responded, the options narrow significantly. Internet-based cognitive behavioral therapy has been studied for medically elevated prolonged grief disorder, though the evidence base remains limited.

The pharmacotherapy evidence base remains thin and largely uncontrolled.

What Ketamine-Assisted Therapy Showed in Mindbloom's Grief Research

Mindbloom's published analysis of 503 bereaved adults is the first publicly available outcomes analysis of ketamine-assisted therapy focused on prolonged grief disorder.⁶ No other published cohort of its kind matches this sample size.

The median time since loss for participants was 18 months. 64% of the group had been grieving for over a year.

Prolonged grief disorder is, by definition, the grief that time was supposed to heal and didn't. For many of these participants, the passage of time had not been a treatment — it had been a reminder that something was wrong.

The headline outcomes from the retrospective cohort include:

• Broad improvement: 90% of completers reported any improvement in their grief symptoms.
• Meaningful response: 76% had a measurable reduction in grief, defined as a 5-point or greater response on the PGD-13 scale.
• Diagnostic remission: 73% no longer met ICD-11 criteria for prolonged grief disorder.

The biggest single improvement in the analysis came within the first two sessions — within approximately two weeks.⁶ For people who had been grieving for a median of 18 months, many of them past the point where time alone was going to help, that timeline matters.⁶ The standard grief therapy course takes approximately 20 weeks. Antidepressants take weeks just to begin working, and as the trial data above shows, they often don't move the grief at all.

By the time traditional treatments are usually measured, 52% of Mindbloom participants had already responded by session two.⁶ Directionally, the data suggests comparable improvement to CGT in significantly less time — though no head-to-head trial has directly compared the two treatments.

The symptom that improved most was identity and role confusion — feeling like yourself again. It is not just the sadness of missing someone. It is the disorientation of no longer knowing who you are without them. That symptom improved in 77% of completers, with an average drop of 35.9%.⁶

Where antidepressants moved depression but not grief, Mindbloom's analysis showed the grief-specific symptoms improving the most. The identity and role confusion symptom improved more than the depression-overlapping emotional pain item, which dropped by 26.4%.⁶ The data suggests the treatment reached the grief itself — not just the depression that had accumulated around it.

The research is a retrospective cohort analysis and a preprint, not a randomized controlled trial. Outcomes are observed rather than proven to be caused by the treatment, and individual results may vary.⁶

How Ketamine Targets What Makes Grief Stick

Ketamine is an NMDA receptor antagonist, and a substantial body of research links it to rapid increases in neuroplasticity. It has been FDA-approved as an anesthetic since 1970 and has been on the World Health Organization List of Essential Medicines since 1985.⁷

That long medical history matters: ketamine is not an experimental compound. It is a well-characterized medication whose effects on the brain are increasingly understood — and some of those effects may map directly onto what prolonged grief does to the brain. Chronic grief is associated with synaptic atrophy, HPA axis dysregulation, and default mode network hyperconnectivity.

Ketamine temporarily blocks NMDA receptors, triggering a downstream surge in glutamate release. That surge activates AMPA receptors and drives a rapid release of brain-derived neurotrophic factor, which promotes synaptogenesis.⁸

This process may reverse the synaptic atrophy associated with chronic grief, rebuilding neural connections that support cognitive flexibility, emotional regulation, and prefrontal function.

Prefrontal hypofunction is closely linked to an impaired sense of self, executive function deficits, and a reduced capacity to imagine a future. Restoring prefrontal connectivity may be one reason identity-related symptoms respond so well to ketamine.

Ketamine also reduces default mode network hyperconnectivity during sessions.⁹ The default mode network is associated with rumination and preoccupation. The dissociative state ketamine produces can temporarily loosen habitual thought patterns, creating a window for new cognitive frameworks to take hold.

What the Mindbloom Program Looks Like

Mindbloom's grief outcomes came from a specific, protocol-driven care model. The grief program includes six guided sessions over approximately four to six weeks.

Sessions are completed at home with medical oversight, guide coaching, and integration support.

Ketamine is FDA-approved as an anesthetic; its use for grief is off-label (see Off-Label Use Disclosure below).

The outcomes observed in the research are inseparable from the comprehensive protocol. The Mindbloom program components include:

• Medical evaluation: A comprehensive provider assessment and personalized treatment plan.
• Supervised sessions: At-home treatments with a peer treatment monitor present, which is required.
• Preparation and integration: App-guided exercises and one-on-one guide coaching sessions.
• Ongoing support: Unlimited guide messaging and Group Integration Circles.
• Experiential toolkit: A Bloombox containing all necessary materials for your sessions.

Mindbloom evaluates eligibility based on medical symptoms, not the specific source of the loss. A licensed provider evaluates each person individually, including potential drug interactions, to ensure safety and appropriateness.

For contraindications and safety details, see Important Safety Information below.

Mindbloom offers programs of 6, 12, or 18 sessions. After you select a program, a licensed provider conducts a comprehensive medical evaluation to determine whether treatment is medically appropriate and to personalize your care plan.

Mindbloom's at-home ketamine therapy starts at $165 per session for an 18-session program, billed in monthly installments. The 6-session program is $215 per session, billed as $430 per month for three months, totaling $1,290.

Returning clients receive preferred pricing as a benefit of continuing care. They pay as little as $129 per session for an 18-session program.

Conclusion

Standard depression treatments were not designed to address prolonged grief disorder, which is why traditional therapy and antidepressants may not have helped you find relief.

Complicated Grief Treatment has the strongest randomized-trial support among psychotherapies for prolonged grief disorder, but significant access barriers leave many people without care. Antidepressants have not been shown to treat the grief itself.

Mindbloom's analysis is the first ketamine-assisted therapy option with published grief-specific outcomes data at scale. In Mindbloom's published analysis, 90% of completers reported symptom improvement and 76% responded to treatment.

Crucially, the biggest improvement came within two sessions — and the symptom that improved most was the one that sits at the heart of prolonged grief: no longer feeling like yourself.

If you have been stuck for a long time, it may not be that nothing works for you. It may simply be that you have not yet tried something designed for what you are actually going through.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.